effect of heparin in combined with magnesium sulfate on the blood gas and blood viscosity in patients with pulmonary heart failure

Objective: To observe the effect of heparin in combined with magnesium sulfate on the blood gas indicators and blood viscosity in patients with pulmonary heart disease merged with respiratory failure. Methods: A total of 80 patients with pulmonary heart disease merged with respiratory failure who were admitted in our hospital were included in the study and randomized into the observation group (n=40) and the control group (n=40). The patients in the control group were given routine symptomatic treatments of pulmonary heart disease. On the above basis, the patients in the observation group were given intravenous drip of heparin and magnesium sulfate. The patients in the two groups were treated for 2 weeks. The blood gas indicators, blood viscosity indicators, PAPs, SBP, and DBP in the two groups were compared. The clinical efficacy in the two groups was evaluated. Results: After 2-week treatment, PaO2 and PaCO2 in the two groups were improved, pH value was not significantly changed, PaO2 in the observation group was significantly higher than that in the control group, while PaCO2 was significantly lower than that in the control group. The hemorheology indicators after treatment in the two groups were significantly reduced when compared with before treatment, among which the comparison of WBV, PV, Hct, and EAI between the two groups was statistically significant, and PAPs after treatment in the observation group was significantly reduced when compared with the control group. SBP and DBP after treatment in the two groups were not significantly changed. Conclusions: Heparin in combined with magnesium sulfate in the treatment of pulmonary heart disease merged with respiratory failure can improve the blood gas indicators and blood viscosity indicators, and reduce SBP of pulmonary artery, with a higher efficacy; therefore, it deserves to be widely recommended in the clinic.